Global Rare Disease Treatment Market By Application (Adults, Children), By Route of Administration (Oral, Injectable), By Indication (Hematology, Oncology, Musculoskeletal, Genetic Disorder, Envenomation, Cardiology & Pulmonology, Endocrinology, Metabolic Disorders, Neurologic diseases, Infectious Diseases, Immunodeficiency, Inherited disorder, Cushing’s disease and Cushing syndrome, Others), By End-User (Hospitals and Clinics, Specialty centers, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Rare diseases are those with a prevalence of fewer than 5 cases per 10,000 people in the European Union. Because of their genetic basis, the majority of instances are detected during childhood, while others are congenital malformations. There are between 5000 and 8000 rare diseases known, with 250–280 new ones described each year. More than 70% of these rare genetic disorders (and 70% have predominantly pediatric-onset) impact 3–4% of all births. Genomics and other recently emerging omics methods hold the key to new rare disease diagnostics and therapeutics. These new technologies, which allow researchers to investigate how diseases affect the entire genome, proteins, lipids, and metabolites in the human body, are generating data on a massive scale previously undiscovered in biomedical research. The increasing prevalence of rare diseases has pushed key players to create novel and enhanced treatments, which are expected to drive the rare disease treatment market in the coming years. The government bodies also provide support for the treatment of rare diseases. In India, for instance, the Central Government would provide financial assistance up to Rs. 20 lakh through the Rashtriya Arogaya Nidhi Umbrella Scheme for the treatment of rare diseases that require a one-time treatment. Beneficiaries for such financial support would not be confined to BPL families but would be expanded to about 40% of the population who are qualified for treatment at government tertiary hospitals under the 23-norms Pradhan Mantri Jan Arogya Yojana.
As of July 22, 2021, the COVID-19 pandemic has afflicted around 192 million individuals worldwide, resulting in 4.13 million deaths. Government bodies in various countries declared strict lockdowns in order to limit the spread of the disease. While this disease mostly affects the lungs, resulting in pneumonia and acute respiratory distress syndrome, it also has a negative impact on cancer treatment. The COVID-19 pandemic's impact on rare disease treatment has resulted in decrease and delays in recognizing treatments in the first half of 2020. With the recovery of covid-19 illnesses, prominent players and government bodies are now concentrating on rare chronic diseases. Furthermore, the increased promise of innovation in drug development for rare diseases will give new prospects for the expansion of the rare disease treatment market in the healthcare sector in the near future.
In terms of revenue, the global rare disease treatment market is growing at a CAGR of 15.76% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Rare Disease Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2030
Application Outlook
Based on application, the global rare disease treatment market has been primarily segmented into adults and children. The children segment holds a significant share of the market in 2021. Rare diseases affect a significant fraction of the population in any country, which, according to widely accepted international studies, ranges between 6% and 8%. Genetic disorders, rare cancer, infectious tropical diseases, and degenerative diseases are examples of rare diseases. Because 80 percent of rare diseases are genetic in nature, they disproportionately affect children.
Route of Administration Outlook
Based on route of administration, the global rare disease treatment market has been segmented into oral and injectable. Drug injection is a method of providing a drug into the bloodstream using a hollow hypodermic needle penetrated through the skin and into the body. Some market participants provide injectable pharmaceuticals, such as AOP Orphan Pharmaceuticals GmbH, a European firm specializing in the discovery, marketing, and distribution of medicines for persons suffering from rare and difficult diseases. The company developed an infusion medication solution for rare disorders.
Indication Outlook
Based on indication, the global rare disease treatment market has been segmented into hematology, oncology, musculoskeletal, genetic disorder, envenomation, cardiology & pulmonology, endocrinology, metabolic disorders, neurologic diseases, infectious diseases, immunodeficiency, inherited disorder, cushing’s disease and cushing syndrome, and others. The oncology segment is estimated to expand at the highest CAGR during the forecast period due to increasing prevalence of several types of cancer disorders in the world. According to the National Cancer Institute, rare cancers are those that impact fewer than 40,000 people in the United States annually. They are responsible for 27% of all cancers and 25% of cancer deaths.
End-User Outlook
Based on end-user, the global rare disease treatment market has been segmented into hospitals and clinics, specialty centers, and others. The specialty centers segment is projected to be the fastest emerging segment over the forecast period. Specialty centers provide a wide range of cost-effective facilities than hospitals. Furthermore, the increasing number of specialty centers in the developed and developing economies is contributing for the segment growth in the coming years.
Region Outlook
Based on regions, North America held the highest share of the worldwide rare disease treatment market in 2021, owing to increased FDA clearance for rare disease medication, reimbursement availability, and increased research & development in this region. Prominent players continue to spend on research and development for rare diseases treatment and expand their presence in the market. For instance, ERGOMED plc, a Clinical Research Organization specializing in rare disease drug development based in the United States, has announced the opening of its Rare Disease Innovation Center in February 2022. The Rare Disease Innovation Center will provide best-in-class worldwide solutions to rare disease sponsors' concerns, allowing them to minimize clinical trial timeframes, improve patient experience, and bring efficient rare disease treatments to market more quickly.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of rare disease treatment market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the global rare disease treatment market are listed below:
- AbbVie Inc.
- Alexion Pharmaceuticals Inc
- Amgen Inc.
- AOP Orphan Pharmaceuticals GmbH
- AstraZeneca
- Bayer AG
- CELGENE CORPORATION
- CSL
- Eisai Co., Ltd.
- Janssen Research & Development, LLC
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Rare Disease Therapeutics, Inc.
- RECORDATI S.p.A.
- Sanofi
- Shire
- Other Market Participants
Global Rare Disease Treatment Market:
- By Application
- Adults
- Children
- By Route of Administration
- Oral
- Injectable
- By Indication
- Hematology
- Oncology
- Musculoskeletal
- Genetic Disorder
- Envenomation
- Cardiology & Pulmonology
- Endocrinology
- Metabolic Disorders
- Neurologic diseases
- Infectious Diseases
- Immunodeficiency
- Inherited disorder
- Cushing’s disease and Cushing syndrome
- Others
- By End-User
- Hospitals and Clinics
- Specialty centers
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Rare Disease Treatment Market
6.
Market
Synopsis: Rare Disease Treatment Market
7.
Rare
Disease Treatment Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Rare Disease Treatment Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Rare Disease Treatment Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Rare Disease Treatment
Market
8.
Global
Rare Disease Treatment Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Rare Disease Treatment Market Revenue
(US$ Mn)
8.2. Global Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
8.2.1. Adults
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 -
2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. Children
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 -
2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Application
9.
Global
Rare Disease Treatment Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
9.2.1. Oral
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 -
2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Injectable
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 -
2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Route of Administration
10. Global Rare Disease Treatment Market
Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
10.2.1. Hematology
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Oncology
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Musculoskeletal
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Genetic Disorder
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.2.5. Envenomation
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 -
2021
10.2.5.3. Market Forecast, 2022 – 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2021
10.2.5.5.1.2. Market Forecast, 2022 – 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2021
10.2.5.5.2.2. Market Forecast, 2022 – 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2021
10.2.5.5.3.2. Market Forecast, 2022 – 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2021
10.2.5.5.4.2. Market Forecast, 2022 – 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2021
10.2.5.5.5.2. Market Forecast, 2022 – 2030
10.2.6. Cardiology and Pulmonology
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 -
2021
10.2.6.3. Market Forecast, 2022 – 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 - 2021
10.2.6.5.1.2. Market Forecast, 2022 – 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 - 2021
10.2.6.5.2.2. Market Forecast, 2022 – 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 - 2021
10.2.6.5.3.2. Market Forecast, 2022 – 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 - 2021
10.2.6.5.4.2. Market Forecast, 2022 – 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 - 2021
10.2.6.5.5.2. Market Forecast, 2022 – 2030
10.2.7. Endocrinology
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 -
2021
10.2.7.3. Market Forecast, 2022 – 2030
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2015 - 2021
10.2.7.5.1.2. Market Forecast, 2022 – 2030
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2015 - 2021
10.2.7.5.2.2. Market Forecast, 2022 – 2030
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 - 2021
10.2.7.5.3.2. Market Forecast, 2022 – 2030
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 - 2021
10.2.7.5.4.2. Market Forecast, 2022 – 2030
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2015 - 2021
10.2.7.5.5.2. Market Forecast, 2022 – 2030
10.2.8. Metabolic Disorders
10.2.8.1. Definition
10.2.8.2. Market Estimation and Penetration, 2015 -
2021
10.2.8.3. Market Forecast, 2022 – 2030
10.2.8.4. Compound Annual Growth Rate (CAGR)
10.2.8.5. Regional Bifurcation
10.2.8.5.1. North America
10.2.8.5.1.1. Market Estimation, 2015 - 2021
10.2.8.5.1.2. Market Forecast, 2022 – 2030
10.2.8.5.2. Europe
10.2.8.5.2.1. Market Estimation, 2015 - 2021
10.2.8.5.2.2. Market Forecast, 2022 – 2030
10.2.8.5.3. Asia Pacific
10.2.8.5.3.1. Market Estimation, 2015 - 2021
10.2.8.5.3.2. Market Forecast, 2022 – 2030
10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2015 - 2021
10.2.8.5.4.2. Market Forecast, 2022 – 2030
10.2.8.5.5. Latin America
10.2.8.5.5.1. Market Estimation, 2015 - 2021
10.2.8.5.5.2. Market Forecast, 2022 – 2030
10.2.9. Neurologic diseases
10.2.9.1. Definition
10.2.9.2. Market Estimation and Penetration, 2015 -
2021
10.2.9.3. Market Forecast, 2022 – 2030
10.2.9.4. Compound Annual Growth Rate (CAGR)
10.2.9.5. Regional Bifurcation
10.2.9.5.1. North America
10.2.9.5.1.1. Market Estimation, 2015 - 2021
10.2.9.5.1.2. Market Forecast, 2022 – 2030
10.2.9.5.2. Europe
10.2.9.5.2.1. Market Estimation, 2015 - 2021
10.2.9.5.2.2. Market Forecast, 2022 – 2030
10.2.9.5.3. Asia Pacific
10.2.9.5.3.1. Market Estimation, 2015 - 2021
10.2.9.5.3.2. Market Forecast, 2022 – 2030
10.2.9.5.4. Middle East and Africa
10.2.9.5.4.1. Market Estimation, 2015 - 2021
10.2.9.5.4.2. Market Forecast, 2022 – 2030
10.2.9.5.5. Latin America
10.2.9.5.5.1. Market Estimation, 2015 - 2021
10.2.9.5.5.2. Market Forecast, 2022 – 2030
10.2.10. Infectious Diseases
10.2.10.1. Definition
10.2.10.2. Market Estimation and Penetration, 2015 -
2021
10.2.10.3. Market Forecast, 2022 – 2030
10.2.10.4. Compound Annual Growth Rate (CAGR)
10.2.10.5. Regional Bifurcation
10.2.10.5.1. North America
10.2.10.5.1.1. Market Estimation, 2015 - 2021
10.2.10.5.1.2. Market Forecast, 2022 – 2030
10.2.10.5.2. Europe
10.2.10.5.2.1. Market Estimation, 2015 - 2021
10.2.10.5.2.2. Market Forecast, 2022 – 2030
10.2.10.5.3. Asia Pacific
10.2.10.5.3.1. Market Estimation, 2015 - 2021
10.2.10.5.3.2. Market Forecast, 2022 – 2030
10.2.10.5.4. Middle East and Africa
10.2.10.5.4.1. Market Estimation, 2015 - 2021
10.2.10.5.4.2. Market Forecast, 2022 – 2030
10.2.10.5.5. Latin America
10.2.10.5.5.1. Market Estimation, 2015 - 2021
10.2.10.5.5.2. Market Forecast, 2022 – 2030
10.2.11. Immunodeficiency
10.2.11.1. Definition
10.2.11.2. Market Estimation and Penetration, 2015 -
2021
10.2.11.3. Market Forecast, 2022 – 2030
10.2.11.4. Compound Annual Growth Rate (CAGR)
10.2.11.5. Regional Bifurcation
10.2.11.5.1. North America
10.2.11.5.1.1. Market Estimation, 2015 - 2021
10.2.11.5.1.2. Market Forecast, 2022 – 2030
10.2.11.5.2. Europe
10.2.11.5.2.1. Market Estimation, 2015 - 2021
10.2.11.5.2.2. Market Forecast, 2022 – 2030
10.2.11.5.3. Asia Pacific
10.2.11.5.3.1. Market Estimation, 2015 - 2021
10.2.11.5.3.2. Market Forecast, 2022 – 2030
10.2.11.5.4. Middle East and Africa
10.2.11.5.4.1. Market Estimation, 2015 - 2021
10.2.11.5.4.2. Market Forecast, 2022 – 2030
10.2.11.5.5. Latin America
10.2.11.5.5.1. Market Estimation, 2015 - 2021
10.2.11.5.5.2. Market Forecast, 2022 – 2030
10.2.12. Inherited disorder
10.2.12.1. Definition
10.2.12.2. Market Estimation and Penetration, 2015 -
2021
10.2.12.3. Market Forecast, 2022 – 2030
10.2.12.4. Compound Annual Growth Rate (CAGR)
10.2.12.5. Regional Bifurcation
10.2.12.5.1. North America
10.2.12.5.1.1. Market Estimation, 2015 - 2021
10.2.12.5.1.2. Market Forecast, 2022 – 2030
10.2.12.5.2. Europe
10.2.12.5.2.1. Market Estimation, 2015 - 2021
10.2.12.5.2.2. Market Forecast, 2022 – 2030
10.2.12.5.3. Asia Pacific
10.2.12.5.3.1. Market Estimation, 2015 - 2021
10.2.12.5.3.2. Market Forecast, 2022 – 2030
10.2.12.5.4. Middle East and Africa
10.2.12.5.4.1. Market Estimation, 2015 - 2021
10.2.12.5.4.2. Market Forecast, 2022 – 2030
10.2.12.5.5. Latin America
10.2.12.5.5.1. Market Estimation, 2015 - 2021
10.2.12.5.5.2. Market Forecast, 2022 – 2030
10.2.13. Cushing’s disease and Cushing syndrome
10.2.13.1. Definition
10.2.13.2. Market Estimation and Penetration, 2015 -
2021
10.2.13.3. Market Forecast, 2022 – 2030
10.2.13.4. Compound Annual Growth Rate (CAGR)
10.2.13.5. Regional Bifurcation
10.2.13.5.1. North America
10.2.13.5.1.1. Market Estimation, 2015 - 2021
10.2.13.5.1.2. Market Forecast, 2022 – 2030
10.2.13.5.2. Europe
10.2.13.5.2.1. Market Estimation, 2015 - 2021
10.2.13.5.2.2. Market Forecast, 2022 – 2030
10.2.13.5.3. Asia Pacific
10.2.13.5.3.1. Market Estimation, 2015 - 2021
10.2.13.5.3.2. Market Forecast, 2022 – 2030
10.2.13.5.4. Middle East and Africa
10.2.13.5.4.1. Market Estimation, 2015 - 2021
10.2.13.5.4.2. Market Forecast, 2022 – 2030
10.2.13.5.5. Latin America
10.2.13.5.5.1. Market Estimation, 2015 - 2021
10.2.13.5.5.2. Market Forecast, 2022 – 2030
10.2.14. Others
10.2.14.1. Definition
10.2.14.2. Market Estimation and Penetration, 2015 -
2021
10.2.14.3. Market Forecast, 2022 – 2030
10.2.14.4. Compound Annual Growth Rate (CAGR)
10.2.14.5. Regional Bifurcation
10.2.14.5.1. North America
10.2.14.5.1.1. Market Estimation, 2015 - 2021
10.2.14.5.1.2. Market Forecast, 2022 – 2030
10.2.14.5.2. Europe
10.2.14.5.2.1. Market Estimation, 2015 - 2021
10.2.14.5.2.2. Market Forecast, 2022 – 2030
10.2.14.5.3. Asia Pacific
10.2.14.5.3.1. Market Estimation, 2015 - 2021
10.2.14.5.3.2. Market Forecast, 2022 – 2030
10.2.14.5.4. Middle East and Africa
10.2.14.5.4.1. Market Estimation, 2015 - 2021
10.2.14.5.4.2. Market Forecast, 2022 – 2030
10.2.14.5.5. Latin America
10.2.14.5.5.1. Market Estimation, 2015 - 2021
10.2.14.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Indication
11. Global Rare Disease Treatment Market
Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
11.2.1. Hospitals and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 -
2021
11.2.1.3. Market Forecast, 2022 – 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Specialty centers
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 -
2021
11.2.2.3. Market Forecast, 2022 – 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 -
2021
11.2.3.3. Market Forecast, 2022 – 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By End-User
12. North America Rare Disease Treatment Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. North America Rare Disease Treatment Market
Revenue (US$ Mn)
12.2. North America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
12.2.1. Adults
12.2.2. Children
12.3. North America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
12.3.1. Oral
12.3.2. Injectable
12.4. North America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
12.4.1. Hematology
12.4.2. Oncology
12.4.3. Musculoskeletal
12.4.4. Genetic Disorder
12.4.5. Envenomation
12.4.6. Cardiology and Pulmonology
12.4.7. Endocrinology
12.4.8. Metabolic Disorders
12.4.9. Neurologic diseases
12.4.10. Infectious Diseases
12.4.11. Immunodeficiency
12.4.12. Inherited disorder
12.4.13. Cushing’s disease and Cushing syndrome
12.4.14. Others
12.5. North America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
12.5.1. Hospitals and Clinics
12.5.2. Specialty centers
12.5.3. Others
12.6. North America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.1.1.1. Adults
12.6.1.1.2. Children
12.6.1.2. U.S Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.6.1.2.1. Oral
12.6.1.2.2. Injectable
12.6.1.3. U.S Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
12.6.1.3.1. Hematology
12.6.1.3.2. Oncology
12.6.1.3.3. Musculoskeletal
12.6.1.3.4. Genetic Disorder
12.6.1.3.5. Envenomation
12.6.1.3.6. Cardiology and Pulmonology
12.6.1.3.7. Endocrinology
12.6.1.3.8. Metabolic Disorders
12.6.1.3.9. Neurologic diseases
12.6.1.3.10. Infectious Diseases
12.6.1.3.11. Immunodeficiency
12.6.1.3.12. Inherited disorder
12.6.1.3.13. Cushing’s disease and Cushing syndrome
12.6.1.3.14. Others
12.6.1.4. U.S Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Specialty centers
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.2.1.1. Adults
12.6.2.1.2. Children
12.6.2.2. Canada Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.6.2.2.1. Oral
12.6.2.2.2. Injectable
12.6.2.3. Canada Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
12.6.2.3.1. Hematology
12.6.2.3.2. Oncology
12.6.2.3.3. Musculoskeletal
12.6.2.3.4. Genetic Disorder
12.6.2.3.5. Envenomation
12.6.2.3.6. Cardiology and Pulmonology
12.6.2.3.7. Endocrinology
12.6.2.3.8. Metabolic Disorders
12.6.2.3.9. Neurologic diseases
12.6.2.3.10. Infectious Diseases
12.6.2.3.11. Immunodeficiency
12.6.2.3.12. Inherited disorder
12.6.2.3.13. Cushing’s disease and Cushing syndrome
12.6.2.3.14. Others
12.6.2.4. Canada Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Specialty centers
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.3.1.1. Adults
12.6.3.1.2. Children
12.6.3.2. Mexico Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.6.3.2.1. Oral
12.6.3.2.2. Injectable
12.6.3.3. Mexico Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
12.6.3.3.1. Hematology
12.6.3.3.2. Oncology
12.6.3.3.3. Musculoskeletal
12.6.3.3.4. Genetic Disorder
12.6.3.3.5. Envenomation
12.6.3.3.6. Cardiology and Pulmonology
12.6.3.3.7. Endocrinology
12.6.3.3.8. Metabolic Disorders
12.6.3.3.9. Neurologic diseases
12.6.3.3.10. Infectious Diseases
12.6.3.3.11. Immunodeficiency
12.6.3.3.12. Inherited disorder
12.6.3.3.13. Cushing’s disease and Cushing syndrome
12.6.3.3.14. Others
12.6.3.4. Mexico Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Specialty centers
12.6.3.4.3. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Application
12.6.4.1.1. Adults
12.6.4.1.2. Children
12.6.4.2. Rest of North America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.4.2.1. Oral
12.6.4.2.2. Injectable
12.6.4.3. Rest of North America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Indication
12.6.4.3.1. Hematology
12.6.4.3.2. Oncology
12.6.4.3.3. Musculoskeletal
12.6.4.3.4. Genetic Disorder
12.6.4.3.5. Envenomation
12.6.4.3.6. Cardiology and Pulmonology
12.6.4.3.7. Endocrinology
12.6.4.3.8. Metabolic Disorders
12.6.4.3.9. Neurologic diseases
12.6.4.3.10. Infectious Diseases
12.6.4.3.11. Immunodeficiency
12.6.4.3.12. Inherited disorder
12.6.4.3.13. Cushing’s disease and Cushing syndrome
12.6.4.3.14. Others
12.6.4.4. Rest of North America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By End-User
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Specialty centers
12.6.4.4.3. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Indication
12.7.5. By End-User
13. Europe Rare Disease Treatment Market
Analysis and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Europe Rare Disease Treatment Market Revenue
(US$ Mn)
13.2. Europe Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
13.2.1. Adults
13.2.2. Children
13.3. Europe Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.3.1. Oral
13.3.2. Injectable
13.4. Europe Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
13.4.1. Hematology
13.4.2. Oncology
13.4.3. Musculoskeletal
13.4.4. Genetic Disorder
13.4.5. Envenomation
13.4.6. Cardiology and Pulmonology
13.4.7. Endocrinology
13.4.8. Metabolic Disorders
13.4.9. Neurologic diseases
13.4.10. Infectious Diseases
13.4.11. Immunodeficiency
13.4.12. Inherited disorder
13.4.13. Cushing’s disease and Cushing syndrome
13.4.14. Others
13.5. Europe Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
13.5.1. Hospitals and Clinics
13.5.2. Specialty centers
13.5.3. Others
13.6. Europe Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.1.1.1. Adults
13.6.1.1.2. Children
13.6.1.2. France Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.1.2.1. Oral
13.6.1.2.2. Injectable
13.6.1.3. France Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.1.3.1. Hematology
13.6.1.3.2. Oncology
13.6.1.3.3. Musculoskeletal
13.6.1.3.4. Genetic Disorder
13.6.1.3.5. Envenomation
13.6.1.3.6. Cardiology and Pulmonology
13.6.1.3.7. Endocrinology
13.6.1.3.8. Metabolic Disorders
13.6.1.3.9. Neurologic diseases
13.6.1.3.10. Infectious Diseases
13.6.1.3.11. Immunodeficiency
13.6.1.3.12. Inherited disorder
13.6.1.3.13. Cushing’s disease and Cushing syndrome
13.6.1.3.14. Others
13.6.1.4. France Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Specialty centers
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.2.1.1. Adults
13.6.2.1.2. Children
13.6.2.2. The UK Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.2.2.1. Oral
13.6.2.2.2. Injectable
13.6.2.3. The UK Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.2.3.1. Hematology
13.6.2.3.2. Oncology
13.6.2.3.3. Musculoskeletal
13.6.2.3.4. Genetic Disorder
13.6.2.3.5. Envenomation
13.6.2.3.6. Cardiology and Pulmonology
13.6.2.3.7. Endocrinology
13.6.2.3.8. Metabolic Disorders
13.6.2.3.9. Neurologic diseases
13.6.2.3.10. Infectious Diseases
13.6.2.3.11. Immunodeficiency
13.6.2.3.12. Inherited disorder
13.6.2.3.13. Cushing’s disease and Cushing syndrome
13.6.2.3.14. Others
13.6.2.4. The UK Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Specialty centers
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.3.1.1. Adults
13.6.3.1.2. Children
13.6.3.2. Spain Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.3.2.1. Oral
13.6.3.2.2. Injectable
13.6.3.3. Spain Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.3.3.1. Hematology
13.6.3.3.2. Oncology
13.6.3.3.3. Musculoskeletal
13.6.3.3.4. Genetic Disorder
13.6.3.3.5. Envenomation
13.6.3.3.6. Cardiology and Pulmonology
13.6.3.3.7. Endocrinology
13.6.3.3.8. Metabolic Disorders
13.6.3.3.9. Neurologic diseases
13.6.3.3.10. Infectious Diseases
13.6.3.3.11. Immunodeficiency
13.6.3.3.12. Inherited disorder
13.6.3.3.13. Cushing’s disease and Cushing syndrome
13.6.3.3.14. Others
13.6.3.4. Spain Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Specialty centers
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.4.1.1. Adults
13.6.4.1.2. Children
13.6.4.2. Germany Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.4.2.1. Oral
13.6.4.2.2. Injectable
13.6.4.3. Germany Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.4.3.1. Hematology
13.6.4.3.2. Oncology
13.6.4.3.3. Musculoskeletal
13.6.4.3.4. Genetic Disorder
13.6.4.3.5. Envenomation
13.6.4.3.6. Cardiology and Pulmonology
13.6.4.3.7. Endocrinology
13.6.4.3.8. Metabolic Disorders
13.6.4.3.9. Neurologic diseases
13.6.4.3.10. Infectious Diseases
13.6.4.3.11. Immunodeficiency
13.6.4.3.12. Inherited disorder
13.6.4.3.13. Cushing’s disease and Cushing syndrome
13.6.4.3.14. Others
13.6.4.4. Germany Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Specialty centers
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.5.1.1. Adults
13.6.5.1.2. Children
13.6.5.2. Italy Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.5.2.1. Oral
13.6.5.2.2. Injectable
13.6.5.3. Italy Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.5.3.1. Hematology
13.6.5.3.2. Oncology
13.6.5.3.3. Musculoskeletal
13.6.5.3.4. Genetic Disorder
13.6.5.3.5. Envenomation
13.6.5.3.6. Cardiology and Pulmonology
13.6.5.3.7. Endocrinology
13.6.5.3.8. Metabolic Disorders
13.6.5.3.9. Neurologic diseases
13.6.5.3.10. Infectious Diseases
13.6.5.3.11. Immunodeficiency
13.6.5.3.12. Inherited disorder
13.6.5.3.13. Cushing’s disease and Cushing syndrome
13.6.5.3.14. Others
13.6.5.4. Italy Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Specialty centers
13.6.5.4.3. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Application
13.6.6.1.1. Adults
13.6.6.1.2. Children
13.6.6.2. Nordic Countries Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.6.2.1. Oral
13.6.6.2.2. Injectable
13.6.6.3. Nordic Countries Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Indication
13.6.6.3.1. Hematology
13.6.6.3.2. Oncology
13.6.6.3.3. Musculoskeletal
13.6.6.3.4. Genetic Disorder
13.6.6.3.5. Envenomation
13.6.6.3.6. Cardiology and Pulmonology
13.6.6.3.7. Endocrinology
13.6.6.3.8. Metabolic Disorders
13.6.6.3.9. Neurologic diseases
13.6.6.3.10. Infectious Diseases
13.6.6.3.11. Immunodeficiency
13.6.6.3.12. Inherited disorder
13.6.6.3.13. Cushing’s disease and Cushing syndrome
13.6.6.3.14. Others
13.6.6.4. Nordic Countries Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Specialty centers
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.7.1.1. Adults
13.6.7.1.2. Children
13.6.7.2. Benelux Union Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.7.2.1. Oral
13.6.7.2.2. Injectable
13.6.7.3. Benelux Union Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
13.6.7.3.1. Hematology
13.6.7.3.2. Oncology
13.6.7.3.3. Musculoskeletal
13.6.7.3.4. Genetic Disorder
13.6.7.3.5. Envenomation
13.6.7.3.6. Cardiology and Pulmonology
13.6.7.3.7. Endocrinology
13.6.7.3.8. Metabolic Disorders
13.6.7.3.9. Neurologic diseases
13.6.7.3.10. Infectious Diseases
13.6.7.3.11. Immunodeficiency
13.6.7.3.12. Inherited disorder
13.6.7.3.13. Cushing’s disease and Cushing syndrome
13.6.7.3.14. Others
13.6.7.4. Benelux Union Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Specialty centers
13.6.7.4.3. Others
13.6.7.5. Benelux Union Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.8.1.1. Adults
13.6.8.1.2. Children
13.6.8.2. Rest of Europe Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.6.8.2.1. Oral
13.6.8.2.2. Injectable
13.6.8.3. Rest of Europe Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
13.6.8.3.1. Hematology
13.6.8.3.2. Oncology
13.6.8.3.3. Musculoskeletal
13.6.8.3.4. Genetic Disorder
13.6.8.3.5. Envenomation
13.6.8.3.6. Cardiology and Pulmonology
13.6.8.3.7. Endocrinology
13.6.8.3.8. Metabolic Disorders
13.6.8.3.9. Neurologic diseases
13.6.8.3.10. Infectious Diseases
13.6.8.3.11. Immunodeficiency
13.6.8.3.12. Inherited disorder
13.6.8.3.13. Cushing’s disease and Cushing syndrome
13.6.8.3.14. Others
13.6.8.4. Rest of Europe Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Specialty centers
13.6.8.4.3. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Indication
13.7.5. By End-User
14. Asia Pacific Rare Disease Treatment Market
Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Asia Pacific Rare Disease Treatment Market
Revenue (US$ Mn)
14.2. Asia Pacific Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
14.2.1. Adults
14.2.2. Children
14.3. Asia Pacific Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.3.1. Oral
14.3.2. Injectable
14.4. Asia Pacific Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
14.4.1. Hematology
14.4.2. Oncology
14.4.3. Musculoskeletal
14.4.4. Genetic Disorder
14.4.5. Envenomation
14.4.6. Cardiology and Pulmonology
14.4.7. Endocrinology
14.4.8. Metabolic Disorders
14.4.9. Neurologic diseases
14.4.10. Infectious Diseases
14.4.11. Immunodeficiency
14.4.12. Inherited disorder
14.4.13. Cushing’s disease and Cushing syndrome
14.4.14. Others
14.5. Asia Pacific Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
14.5.1. Hospitals and Clinics
14.5.2. Specialty centers
14.5.3. Others
14.6. Asia Pacific Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.1.1.1. Adults
14.6.1.1.2. Children
14.6.1.2. China Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.1.2.1. Oral
14.6.1.2.2. Injectable
14.6.1.3. China Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
14.6.1.3.1. Hematology
14.6.1.3.2. Oncology
14.6.1.3.3. Musculoskeletal
14.6.1.3.4. Genetic Disorder
14.6.1.3.5. Envenomation
14.6.1.3.6. Cardiology and Pulmonology
14.6.1.3.7. Endocrinology
14.6.1.3.8. Metabolic Disorders
14.6.1.3.9. Neurologic diseases
14.6.1.3.10. Infectious Diseases
14.6.1.3.11. Immunodeficiency
14.6.1.3.12. Inherited disorder
14.6.1.3.13. Cushing’s disease and Cushing syndrome
14.6.1.3.14. Others
14.6.1.4. China Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Specialty centers
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.2.1.1. Adults
14.6.2.1.2. Children
14.6.2.2. Japan Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.2.2.1. Oral
14.6.2.2.2. Injectable
14.6.2.3. Japan Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
14.6.2.3.1. Hematology
14.6.2.3.2. Oncology
14.6.2.3.3. Musculoskeletal
14.6.2.3.4. Genetic Disorder
14.6.2.3.5. Envenomation
14.6.2.3.6. Cardiology and Pulmonology
14.6.2.3.7. Endocrinology
14.6.2.3.8. Metabolic Disorders
14.6.2.3.9. Neurologic diseases
14.6.2.3.10. Infectious Diseases
14.6.2.3.11. Immunodeficiency
14.6.2.3.12. Inherited disorder
14.6.2.3.13. Cushing’s disease and Cushing syndrome
14.6.2.3.14. Others
14.6.2.4. Japan Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Specialty centers
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.3.1.1. Adults
14.6.3.1.2. Children
14.6.3.2. India Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.3.2.1. Oral
14.6.3.2.2. Injectable
14.6.3.3. India Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
14.6.3.3.1. Hematology
14.6.3.3.2. Oncology
14.6.3.3.3. Musculoskeletal
14.6.3.3.4. Genetic Disorder
14.6.3.3.5. Envenomation
14.6.3.3.6. Cardiology and Pulmonology
14.6.3.3.7. Endocrinology
14.6.3.3.8. Metabolic Disorders
14.6.3.3.9. Neurologic diseases
14.6.3.3.10. Infectious Diseases
14.6.3.3.11. Immunodeficiency
14.6.3.3.12. Inherited disorder
14.6.3.3.13. Cushing’s disease and Cushing syndrome
14.6.3.3.14. Others
14.6.3.4. India Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Specialty centers
14.6.3.4.3. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.4.1.1. Adults
14.6.4.1.2. Children
14.6.4.2. New Zealand Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.4.2.1. Oral
14.6.4.2.2. Injectable
14.6.4.3. New Zealand Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
14.6.4.3.1. Hematology
14.6.4.3.2. Oncology
14.6.4.3.3. Musculoskeletal
14.6.4.3.4. Genetic Disorder
14.6.4.3.5. Envenomation
14.6.4.3.6. Cardiology and Pulmonology
14.6.4.3.7. Endocrinology
14.6.4.3.8. Metabolic Disorders
14.6.4.3.9. Neurologic diseases
14.6.4.3.10. Infectious Diseases
14.6.4.3.11. Immunodeficiency
14.6.4.3.12. Inherited disorder
14.6.4.3.13. Cushing’s disease and Cushing syndrome
14.6.4.3.14. Others
14.6.4.4. New Zealand Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Specialty centers
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.5.1.1. Adults
14.6.5.1.2. Children
14.6.5.2. Australia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.5.2.1. Oral
14.6.5.2.2. Injectable
14.6.5.3. Australia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
14.6.5.3.1. Hematology
14.6.5.3.2. Oncology
14.6.5.3.3. Musculoskeletal
14.6.5.3.4. Genetic Disorder
14.6.5.3.5. Envenomation
14.6.5.3.6. Cardiology and Pulmonology
14.6.5.3.7. Endocrinology
14.6.5.3.8. Metabolic Disorders
14.6.5.3.9. Neurologic diseases
14.6.5.3.10. Infectious Diseases
14.6.5.3.11. Immunodeficiency
14.6.5.3.12. Inherited disorder
14.6.5.3.13. Cushing’s disease and Cushing syndrome
14.6.5.3.14. Others
14.6.5.4. Australia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Specialty centers
14.6.5.4.3. Others
14.6.6. South Korea
14.6.6.1. South Korea Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.6.1.1. Adults
14.6.6.1.2. Children
14.6.6.2. South Korea Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.6.2.1. Oral
14.6.6.2.2. Injectable
14.6.6.3. South Korea Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
14.6.6.3.1. Hematology
14.6.6.3.2. Oncology
14.6.6.3.3. Musculoskeletal
14.6.6.3.4. Genetic Disorder
14.6.6.3.5. Envenomation
14.6.6.3.6. Cardiology and Pulmonology
14.6.6.3.7. Endocrinology
14.6.6.3.8. Metabolic Disorders
14.6.6.3.9. Neurologic diseases
14.6.6.3.10. Infectious Diseases
14.6.6.3.11. Immunodeficiency
14.6.6.3.12. Inherited disorder
14.6.6.3.13. Cushing’s disease and Cushing syndrome
14.6.6.3.14. Others
14.6.6.4. South Korea Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Specialty centers
14.6.6.4.3. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.7.1.1. Adults
14.6.7.1.2. Children
14.6.7.2. Southeast Asia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.7.2.1. Oral
14.6.7.2.2. Injectable
14.6.7.3. Southeast Asia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
14.6.7.3.1. Hematology
14.6.7.3.2. Oncology
14.6.7.3.3. Musculoskeletal
14.6.7.3.4. Genetic Disorder
14.6.7.3.5. Envenomation
14.6.7.3.6. Cardiology and Pulmonology
14.6.7.3.7. Endocrinology
14.6.7.3.8. Metabolic Disorders
14.6.7.3.9. Neurologic diseases
14.6.7.3.10. Infectious Diseases
14.6.7.3.11. Immunodeficiency
14.6.7.3.12. Inherited disorder
14.6.7.3.13. Cushing’s disease and Cushing syndrome
14.6.7.3.14. Others
14.6.7.4. Southeast Asia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Specialty centers
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Application
14.6.8.1.1. Adults
14.6.8.1.2. Children
14.6.8.2. Rest of Asia Pacific Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.8.2.1. Oral
14.6.8.2.2. Injectable
14.6.8.3. Rest of Asia Pacific Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Indication
14.6.8.3.1. Hematology
14.6.8.3.2. Oncology
14.6.8.3.3. Musculoskeletal
14.6.8.3.4. Genetic Disorder
14.6.8.3.5. Envenomation
14.6.8.3.6. Cardiology and Pulmonology
14.6.8.3.7. Endocrinology
14.6.8.3.8. Metabolic Disorders
14.6.8.3.9. Neurologic diseases
14.6.8.3.10. Infectious Diseases
14.6.8.3.11. Immunodeficiency
14.6.8.3.12. Inherited disorder
14.6.8.3.13. Cushing’s disease and Cushing syndrome
14.6.8.3.14. Others
14.6.8.4. Rest of Asia Pacific Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By End-User
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Specialty centers
14.6.8.4.3. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Indication
14.7.5. By End-User
15. Middle East and Africa Rare Disease
Treatment Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Middle East and Africa Rare Disease Treatment
Market Revenue (US$ Mn)
15.2. Middle East and Africa Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Application
15.2.1. Adults
15.2.2. Children
15.3. Middle East and Africa Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.3.1. Oral
15.3.2. Injectable
15.4. Middle East and Africa Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Indication
15.4.1. Hematology
15.4.2. Oncology
15.4.3. Musculoskeletal
15.4.4. Genetic Disorder
15.4.5. Envenomation
15.4.6. Cardiology and Pulmonology
15.4.7. Endocrinology
15.4.8. Metabolic Disorders
15.4.9. Neurologic diseases
15.4.10. Infectious Diseases
15.4.11. Immunodeficiency
15.4.12. Inherited disorder
15.4.13. Cushing’s disease and Cushing syndrome
15.4.14. Others
15.5. Middle East and Africa Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1. Hospitals and Clinics
15.5.2. Specialty centers
15.5.3. Others
15.6. Middle East and Africa Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.1.1.1. Adults
15.6.1.1.2. Children
15.6.1.2. Saudi Arabia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.1.2.1. Oral
15.6.1.2.2. Injectable
15.6.1.3. Saudi Arabia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
15.6.1.3.1. Hematology
15.6.1.3.2. Oncology
15.6.1.3.3. Musculoskeletal
15.6.1.3.4. Genetic Disorder
15.6.1.3.5. Envenomation
15.6.1.3.6. Cardiology and Pulmonology
15.6.1.3.7. Endocrinology
15.6.1.3.8. Metabolic Disorders
15.6.1.3.9. Neurologic diseases
15.6.1.3.10. Infectious Diseases
15.6.1.3.11. Immunodeficiency
15.6.1.3.12. Inherited disorder
15.6.1.3.13. Cushing’s disease and Cushing syndrome
15.6.1.3.14. Others
15.6.1.4. Saudi Arabia Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Specialty centers
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.2.1.1. Adults
15.6.2.1.2. Children
15.6.2.2. UAE Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.2.2.1. Oral
15.6.2.2.2. Injectable
15.6.2.3. UAE Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
15.6.2.3.1. Hematology
15.6.2.3.2. Oncology
15.6.2.3.3. Musculoskeletal
15.6.2.3.4. Genetic Disorder
15.6.2.3.5. Envenomation
15.6.2.3.6. Cardiology and Pulmonology
15.6.2.3.7. Endocrinology
15.6.2.3.8. Metabolic Disorders
15.6.2.3.9. Neurologic diseases
15.6.2.3.10. Infectious Diseases
15.6.2.3.11. Immunodeficiency
15.6.2.3.12. Inherited disorder
15.6.2.3.13. Cushing’s disease and Cushing syndrome
15.6.2.3.14. Others
15.6.2.4. UAE Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Specialty centers
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.3.1.1. Adults
15.6.3.1.2. Children
15.6.3.2. Egypt Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.3.2.1. Oral
15.6.3.2.2. Injectable
15.6.3.3. Egypt Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
15.6.3.3.1. Hematology
15.6.3.3.2. Oncology
15.6.3.3.3. Musculoskeletal
15.6.3.3.4. Genetic Disorder
15.6.3.3.5. Envenomation
15.6.3.3.6. Cardiology and Pulmonology
15.6.3.3.7. Endocrinology
15.6.3.3.8. Metabolic Disorders
15.6.3.3.9. Neurologic diseases
15.6.3.3.10. Infectious Diseases
15.6.3.3.11. Immunodeficiency
15.6.3.3.12. Inherited disorder
15.6.3.3.13. Cushing’s disease and Cushing syndrome
15.6.3.3.14. Others
15.6.3.4. Egypt Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Specialty centers
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.4.1.1. Adults
15.6.4.1.2. Children
15.6.4.2. Kuwait Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
15.6.4.2.1. Oral
15.6.4.2.2. Injectable
15.6.4.3. Kuwait Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
15.6.4.3.1. Hematology
15.6.4.3.2. Oncology
15.6.4.3.3. Musculoskeletal
15.6.4.3.4. Genetic Disorder
15.6.4.3.5. Envenomation
15.6.4.3.6. Cardiology and Pulmonology
15.6.4.3.7. Endocrinology
15.6.4.3.8. Metabolic Disorders
15.6.4.3.9. Neurologic diseases
15.6.4.3.10. Infectious Diseases
15.6.4.3.11. Immunodeficiency
15.6.4.3.12. Inherited disorder
15.6.4.3.13. Cushing’s disease and Cushing syndrome
15.6.4.3.14. Others
15.6.4.4. Kuwait Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Specialty centers
15.6.4.4.3. Others
15.6.5. South Africa
15.6.5.1. South Africa Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.5.1.1. Adults
15.6.5.1.2. Children
15.6.5.2. South Africa Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.5.2.1. Oral
15.6.5.2.2. Injectable
15.6.5.3. South Africa Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
15.6.5.3.1. Hematology
15.6.5.3.2. Oncology
15.6.5.3.3. Musculoskeletal
15.6.5.3.4. Genetic Disorder
15.6.5.3.5. Envenomation
15.6.5.3.6. Cardiology and Pulmonology
15.6.5.3.7. Endocrinology
15.6.5.3.8. Metabolic Disorders
15.6.5.3.9. Neurologic diseases
15.6.5.3.10. Infectious Diseases
15.6.5.3.11. Immunodeficiency
15.6.5.3.12. Inherited disorder
15.6.5.3.13. Cushing’s disease and Cushing syndrome
15.6.5.3.14. Others
15.6.5.4. South Africa Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Specialty centers
15.6.5.4.3. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Rare Disease
Treatment Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.1.1. Adults
15.6.6.1.2. Children
15.6.6.2. Rest of Middle East & Africa Rare Disease
Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.2.1. Oral
15.6.6.2.2. Injectable
15.6.6.3. Rest of Middle East & Africa Rare Disease
Treatment Market Revenue (US$ Mn) and Forecasts, By Indication
15.6.6.3.1. Hematology
15.6.6.3.2. Oncology
15.6.6.3.3. Musculoskeletal
15.6.6.3.4. Genetic Disorder
15.6.6.3.5. Envenomation
15.6.6.3.6. Cardiology and Pulmonology
15.6.6.3.7. Endocrinology
15.6.6.3.8. Metabolic Disorders
15.6.6.3.9. Neurologic diseases
15.6.6.3.10. Infectious Diseases
15.6.6.3.11. Immunodeficiency
15.6.6.3.12. Inherited disorder
15.6.6.3.13. Cushing’s disease and Cushing syndrome
15.6.6.3.14. Others
15.6.6.4. Rest of Middle East & Africa Rare Disease
Treatment Market Revenue (US$ Mn) and Forecasts, By End-User
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Specialty centers
15.6.6.4.3. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Application
15.7.3. By Route of Administration
15.7.4. By Indication
15.7.5. By End-User
16. Latin America Rare Disease Treatment Market
Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Latin America Rare Disease Treatment Market
Revenue (US$ Mn)
16.2. Latin America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
16.2.1. Adults
16.2.2. Children
16.3. Latin America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.3.1. Oral
16.3.2. Injectable
16.4. Latin America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
16.4.1. Hematology
16.4.2. Oncology
16.4.3. Musculoskeletal
16.4.4. Genetic Disorder
16.4.5. Envenomation
16.4.6. Cardiology and Pulmonology
16.4.7. Endocrinology
16.4.8. Metabolic Disorders
16.4.9. Neurologic diseases
16.4.10. Infectious Diseases
16.4.11. Immunodeficiency
16.4.12. Inherited disorder
16.4.13. Cushing’s disease and Cushing syndrome
16.4.14. Others
16.5. Latin America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
16.5.1. Hospitals and Clinics
16.5.2. Specialty centers
16.5.3. Others
16.6. Latin America Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.1.1.1. Adults
16.6.1.1.2. Children
16.6.1.2. Brazil Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.6.1.2.1. Oral
16.6.1.2.2. Injectable
16.6.1.3. Brazil Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By Indication
16.6.1.3.1. Hematology
16.6.1.3.2. Oncology
16.6.1.3.3. Musculoskeletal
16.6.1.3.4. Genetic Disorder
16.6.1.3.5. Envenomation
16.6.1.3.6. Cardiology and Pulmonology
16.6.1.3.7. Endocrinology
16.6.1.3.8. Metabolic Disorders
16.6.1.3.9. Neurologic diseases
16.6.1.3.10. Infectious Diseases
16.6.1.3.11. Immunodeficiency
16.6.1.3.12. Inherited disorder
16.6.1.3.13. Cushing’s disease and Cushing syndrome
16.6.1.3.14. Others
16.6.1.4. Brazil Rare Disease Treatment Market Revenue
(US$ Mn) and Forecasts, By End-User
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Specialty centers
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Application
16.6.2.1.1. Adults
16.6.2.1.2. Children
16.6.2.2. Argentina Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.2.2.1. Oral
16.6.2.2.2. Injectable
16.6.2.3. Argentina Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By Indication
16.6.2.3.1. Hematology
16.6.2.3.2. Oncology
16.6.2.3.3. Musculoskeletal
16.6.2.3.4. Genetic Disorder
16.6.2.3.5. Envenomation
16.6.2.3.6. Cardiology and Pulmonology
16.6.2.3.7. Endocrinology
16.6.2.3.8. Metabolic Disorders
16.6.2.3.9. Neurologic diseases
16.6.2.3.10. Infectious Diseases
16.6.2.3.11. Immunodeficiency
16.6.2.3.12. Inherited disorder
16.6.2.3.13. Cushing’s disease and Cushing syndrome
16.6.2.3.14. Others
16.6.2.4. Argentina Rare Disease Treatment Market
Revenue (US$ Mn) and Forecasts, By End-User
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Specialty centers
16.6.2.4.3. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Application
16.6.3.1.1. Adults
16.6.3.1.2. Children
16.6.3.2. Rest of Latin America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.3.2.1. Oral
16.6.3.2.2. Injectable
16.6.3.3. Rest of Latin America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By Indication
16.6.3.3.1. Hematology
16.6.3.3.2. Oncology
16.6.3.3.3. Musculoskeletal
16.6.3.3.4. Genetic Disorder
16.6.3.3.5. Envenomation
16.6.3.3.6. Cardiology and Pulmonology
16.6.3.3.7. Endocrinology
16.6.3.3.8. Metabolic Disorders
16.6.3.3.9. Neurologic diseases
16.6.3.3.10. Infectious Diseases
16.6.3.3.11. Immunodeficiency
16.6.3.3.12. Inherited disorder
16.6.3.3.13. Cushing’s disease and Cushing syndrome
16.6.3.3.14. Others
16.6.3.4. Rest of Latin America Rare Disease Treatment
Market Revenue (US$ Mn) and Forecasts, By End-User
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Specialty centers
16.6.3.4.3. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Application
16.7.3. By Route of Administration
16.7.4. By Indication
16.7.5. By End-User
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. AbbVie Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Alexion Pharmaceuticals Inc
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Amgen Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. AOP Orphan Pharmaceuticals GmbH
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. AstraZeneca
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Bayer AG
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. CELGENE CORPORATION
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. CSL
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Eisai Co., Ltd.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Janssen Research and Development, LLC
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Novartis AG
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Novo Nordisk A/S
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Pfizer Inc.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Rare Disease Therapeutics, Inc.
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. RECORDATI S.p.A.
18.15.1. Company Details
18.15.2. Company Overview
18.15.3. Product Offerings
18.15.4. Key Developments
18.15.5. Financial Analysis
18.15.6. SWOT Analysis
18.15.7. Business Strategies
18.16. Sanofi
18.16.1. Company Details
18.16.2. Company Overview
18.16.3. Product Offerings
18.16.4. Key Developments
18.16.5. Financial Analysis
18.16.6. SWOT Analysis
18.16.7. Business Strategies
18.17. Shire
18.17.1. Company Details
18.17.2. Company Overview
18.17.3. Product Offerings
18.17.4. Key Developments
18.17.5. Financial Analysis
18.17.6. SWOT Analysis
18.17.7. Business Strategies
18.18. Other Market Participants
19. Key Findings
Note: This ToC is tentative and
can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.